60 Degrees Pharmaceuticals, Inc. released an investor presentation outlining its strategy for vector-borne disease therapeutics, highlighting its marketed antimalarial platform ARAKODA as a basis for future indication expansion into babesiosis.
60 Degrees Pharmaceuticals, Inc. released an investor presentation outlining its strategy for vector-borne disease therapeutics, highlighting its marketed antimalarial platform ARAKODA as a basis for future indication expansion into babesiosis.